Boston Scientific Corp (BSX)
Quick ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 865,000 | 952,000 | 426,000 | 570,000 | 928,000 | 338,000 | 276,000 | 325,000 | 1,925,000 | 1,947,000 | 2,675,000 | 2,016,000 | 1,734,000 | 2,022,000 | 1,724,000 | 370,000 | 217,000 | 277,000 | 123,000 | 139,000 |
| Short-term investments | US$ in thousands | — | — | 4,000 | 4,000 | 2,000 | 3,000 | 5,000 | 8,000 | 10,000 | 4,000 | 176,000 | 213,000 | 414,000 | 0 | 0 | 0 | 1,000 | — | 1,000 | 1,000 |
| Receivables | US$ in thousands | 2,228,000 | 2,101,000 | 2,134,000 | 2,076,000 | 1,970,000 | 1,871,000 | 1,917,000 | 1,866,000 | 1,778,000 | 1,669,000 | 1,675,000 | 1,631,000 | 1,531,000 | 1,598,000 | 1,457,000 | 1,702,000 | 1,933,000 | 1,796,000 | 1,712,000 | 1,621,000 |
| Total current liabilities | US$ in thousands | 4,933,000 | 4,579,000 | 4,562,000 | 4,083,000 | 3,803,000 | 3,549,000 | 3,883,000 | 4,275,000 | 4,274,000 | 4,022,000 | 4,073,000 | 3,393,000 | 3,681,000 | 3,302,000 | 3,108,000 | 3,976,000 | 4,866,000 | 4,254,000 | 4,850,000 | 4,479,000 |
| Quick ratio | 0.63 | 0.67 | 0.56 | 0.65 | 0.76 | 0.62 | 0.57 | 0.51 | 0.87 | 0.90 | 1.11 | 1.14 | 1.00 | 1.10 | 1.02 | 0.52 | 0.44 | 0.49 | 0.38 | 0.39 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($865,000K
+ $—K
+ $2,228,000K)
÷ $4,933,000K
= 0.63
The quick ratio measures the ability of a company to meet its short-term obligations using its most liquid assets. In the case of Boston Scientific Corp., the quick ratio has fluctuated over the past eight quarters.
The quick ratio decreased from 0.98 in Q4 2022 to 0.79 in Q4 2023, indicating a decline in the company's ability to cover its current liabilities with its most liquid assets. This downward trend suggests that Boston Scientific Corp. may be facing challenges in maintaining sufficient liquidity to meet its short-term financial obligations.
While the quick ratio improved slightly in Q3 2023 to 0.87, it remained below the previous year's levels. The subsequent decrease to 0.77 in Q2 2023 and again increase to 0.86 in Q1 2023 show continued volatility in the company's liquidity position.
Overall, the quick ratio for Boston Scientific Corp. has shown variability over the past eight quarters, with values ranging from 0.74 to 0.98. Investors and stakeholders may want to closely monitor future changes in the quick ratio to assess the company's ability to effectively manage its short-term liquidity needs.
Peer comparison
Dec 31, 2023